- Achondrogenesis, a rare genetic disorder affecting skeletal development, is drawing growing attention in the medical and pharmaceutical sectors due to its severe impact on prenatal and neonatal health and the need for early and accurate diagnosis through advanced imaging and genetic screening techniques
- The demand for achondrogenesis-related diagnostics and supportive care is primarily driven by increased awareness of rare diseases, expanding availability of prenatal testing, and improved access to specialized medical facilities and genetic counseling services
- North America dominated the achondrogenesis market with the largest revenue share of 39.1% in 2024, supported by advanced healthcare infrastructure, higher prevalence of genetic testing, and proactive initiatives in rare disease research and funding, with the U.S. witnessing significant growth in early diagnosis and patient management through collaborations between research institutions and biotech firms
- Asia-Pacific is expected to be the fastest growing region in the achondrogenesis market during the forecast period due to rising healthcare investments, growing awareness of genetic disorders, and increasing access to prenatal care and diagnostics across emerging economies such as China and India
- Type II segment dominated the achondrogenesis market with a market share of 48.8% in 2024, driven by its relatively higher prevalence compared to Type IA and IB, along with improved clinical recognition and research focus on its genetic causes, particularly COL2A1 gene mutations
